A Phase 2/3 interventional study of Oral Brepocitinib and Placebo in Lichen Planopilaris, sponsored by Priovant Therapeutics, Inc.. Recruiting at 61 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Priovant Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Lichen Planus with a site in United States — 6 open to participants now, 7 under way, 1 of them phase 3. Lichen Planus · United States.
Among the 33 studies in Lichen Planus with a site in United States, this one is the 2nd largest by planned enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2026, is the only one in phase 2/3, and was the 32nd registered.
75 studies on the registry are indexed under Lichen Planus; 16 are open to participants now.
Browse Lichen Planus studies →6 of the 33 studies in Lichen Planus with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Australia, Canada and 1 more country
Ages 18–99
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
The Skin Center Dermatology Group · Sites in United States
Ages 18+
Henry Ford Health System · Sites in United States
Ages 18+
Vaginal Biome Science · Sites in United States, Canada
Ages 18–89 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Lichen Planus studies recruiting now, 6 (50%) set no upper age limit and 3 (25%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 18 · Phase 3 1 · Phase 4 2
First in 1996; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 342 is above the median of 30 across 56 interventional studies indexed under Lichen Planus.
Median enrollment 20 across the 26 interventional studies, 80 across the 7 observational. Of the 23 that completed or were terminated, 12 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 33 have an industry lead sponsor. The 10 most frequent:
Priovant Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Priovant Therapeutics, Inc. has 1 study filed under Lichen Planus — fewer than ten, so there is no comparison to draw.
4 of the studies in Lichen Planus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07487948Icahn School of Medicine at Mount SinaiSafety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris | 2027-04-05 |
| NCT00542373M.D. Anderson Cancer CenterWidefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer | 2027-04-30 |
| NCT06472765Vaginal Biome ScienceVaginal Ecosystem and Network in the United States Study | 2027-05-15 |
| NCT07396168The Skin Center Dermatology GroupNemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study. | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 33 studies in Lichen Planus with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Oral Brepocitinib
Drug: Placebo
Oral
Oral
Proportion of participants achieving IGA score 0/1 and ≥ 2-step reduction from baseline at Week 24
Time frame: Week 24
Change from baseline in LPP symptom numerical rating scale scores at Week 24
Time frame: Week 24
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06700841
Priovant Therapeutics, Inc.